Tolerability and Safety of Primaquine in Papua New Guinean Children 1 to 10 Years of Age
- Author(s)
- Betuela, I; Bassat, Q; Kiniboro, B; Robinson, LJ; Rosanas-Urgell, A; Stanisic, D; Siba, PM; Alonso, PL; Mueller, I;
- Details
- Publication Year 2012-04,Volume 56,Issue #4,Page 2146-2149
- Journal Title
- ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Publication Type
- Journal Article
- Abstract
- Primaquine is currently the only drug available for radical cure of Plasmodium vivax and P. ovale liver infection stages, but limited safety data exist for children <10 years of age. Detailed daily assessments of side effects in glucose-6-phosphate dehydrogenase (G6PD)-normal children treated with 14 days of primaquine plus chloroquine (3 days; n = 252) or artesunate (7 days; n = 141) (0.5 mg/kg of body weight) showed that both treatments are well tolerated, do not lead to reductions in hemoglobin levels, and can thus safely be used in children 1 to 10 years of age.
- Publisher
- AMER SOC MICROBIOLOGY
- Keywords
- PLASMODIUM-VIVAX; MALARIA; FALCIPARUM; DEFICIENCY; THERAPY
- Research Division(s)
- Infection And Immunity
- Link To PubMed Central Version
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3318393/
- Publisher's Version
- https://doi.org/10.1128/AAC.05566-11
- Terms of Use/Rights Notice
- Copyright © 2013 by the American Society for Microbiology
Creation Date: 2012-04-01 12:00:00